Skip to Main Content

Rise and shine, everyone, another busy day is on the way. We can tell because our short person — who now drives but remains shorter than us — has left for another day of work called pamper the camper. And our official mascot is lounging about before his usual morning stroll. As for us, we are firing up the coffee kettle and making cups of stimulation. Our choice today is butter pecan. Feel free to join us. Your neurons will thank you. Meanwhile, here are some items of interest to help you on your journey, which we hope will be productive. Good luck…

Big drug makers and their lobbyists have a message for Congress: Don’t raise taxes on the industry that brought you fast-tracked Covid-19 vaccines, The Wall Street Journal says. Pharma executives, lobbyists, and consultants are mobilizing to fight a sweeping agreement by many of the world’s biggest economies to harmonize corporate taxation around the globe. Earlier this month, 130 countries agreed to broad outlines of a deal to establish a minimum corporate tax of 15%, reducing opportunities for international tax avoidance.


Billy Dunn, the Food and Drug Administration’s chief of neuroscience, has emerged as a key character in the Aduhelm saga — perhaps the most pivotal player inside the FDA to advocate for approval of the controversial Alzheimer’s drug, STAT tells us. That role is at odds with the regulator his colleagues say they have known: an expert with a reputation for hewing to stringent approval standards and demanding drug makers submit unimpeachable data from well-designed clinical trials — a far cry from the messier results submitted by Biogen (BIIB).

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.